Partner Stephen Aschettino was quoted in an ISO & Agent article “Merchants in Legal Hot Water After EMV Shift,” on July 5, 2016. The article discussed how some merchants are facing consumer lawsuits stemming from the introduction of EMV-chip card security at the point of sale. For example, a Wendy’s customer filed a class action against the restaurant alleging that it failed to protect customers’ credit card information, as well as other personally identifiable information. “I think they’re just trying to show that Wendy’s failure to use the EMV chip is some form of negligence. If my analysis is correct, I think that’s very different than the liability shift issue that we in the industry are very worried about.” He continued to explain a lawsuit filed by B&R Supermarket against most of the major card networks and issuers claiming thousands of dollars in losses because of the EMV shift. “Depending on the magnitude of the chargebacks and resources of the merchants, some merchants may be willing to challenge those rules. I do foresee there will be more litigation going forward on these issues.”
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”